Literature DB >> 17364117

Prevalence and risk factors for combined coronary artery disease and aortic aneurysm.

Carlos Romério Costa Ferro1, Dinaldo Cavalcanti de Oliveira, Fábio de Freitas Guimarães Guerra, Alexandre Jorge de Lucena, Fabiana Piech Nunes, Sergio Tranchesi Ortiz, Enilton Sergio Tabosa Egito, Luis Carlos Bento de Sousa, Adib Domingos Jatene, Leopoldo Soares Piegas.   

Abstract

OBJECTIVE: To evaluate CAD prevalence in patients with aortic aneurysm, as well as differences related to aneurysm topographies. To describe the primary risk factors for CAD related to this association and their occasional differences according to AA topographies.
METHODS: This was an open, prospective, nonrandomized study that evaluated 95 patients (66 men and 33 women, mean age 63 +/- 11.8). All patients, asymptomatic for CAD, had undergone aortic CT and coronary angiography. According to the AA topography, they were classified into three groups: 1) patients with thoracic aortic aneurysm (TAA); 2) thoracoabdominal aortic aneurysm (TAAA); and 3) abdominal aortic aneurysm (AAA). A database was created to store information from clinical data and complementary examinations. Statistical analysis was performed using the Students t test or analysis of variance (ANOVA) for continuous variables and chi-square test for categorical variables. P values < 0.05 were considered statistically significant.
RESULTS: CAD prevalence was 63.1%, and AAA was more prevalent than TAA and TAAA (76% vs. 70% vs. 30%, p = 0.001). The comparative analysis of CAD risk factors based on the aortic aneurysm topography revealed that smoking and dyslipidemia were more prevalent among AAA patients (74.5% vs. 42.3% vs. 60%, p = 0.01 and (54.2% vs. 19.9% vs. 60%, p = 0.007, respectively). As for coronary lesion severity in the population of AA patients, 12 (20%) had at least one lesion > or = 70% and 19 (31.6%), > or = 50%. Fifteen patients (25%) had single-vessel disease, 11 (18%) had two-vessel disease, and 34 (57%) had three-vessel disease.
CONCLUSION: Asymptomatic CAD is highly prevalent in AA patients, particularly among those with AAA. Study results suggest the need for diagnostic stratification for CAD in patients with AA, especially those with AAA.

Entities:  

Mesh:

Year:  2007        PMID: 17364117     DOI: 10.1590/s0066-782x2007000100007

Source DB:  PubMed          Journal:  Arq Bras Cardiol        ISSN: 0066-782X            Impact factor:   2.000


  6 in total

1.  Preoperative cardiac evaluation by dipyridamole thallium-201 myocardial perfusion scan provides no benefit in patients with abdominal aortic aneurysm.

Authors:  Sung Shin; Tae-Won Kwon; Yong-Pil Cho; Jong-Young Lee; Hojong Park; Youngjin Han
Journal:  World J Surg       Date:  2013-12       Impact factor: 3.352

2.  Comparison of arterial stiffness and microcirculatory changes following abdominal aortic aneurysm grafting.

Authors:  M A Moloney; S McHugh; D H O' Donnell; R G Casey; E G Kavanagh; P A Grace; P Fitzgerald; D J Bouchier-Hayes
Journal:  Ir J Med Sci       Date:  2010-11-11       Impact factor: 1.568

3.  Role of cardiac evaluation before thoracic endovascular aortic repair.

Authors:  Asvin M Ganapathi; Brian R Englum; Matthew A Schechter; John P Vavalle; J Kevin Harrison; Richard L McCann; G Chad Hughes
Journal:  J Vasc Surg       Date:  2014-06-25       Impact factor: 4.268

4.  Multifocal cholesterol granulomas of the anterior mediastinum.

Authors:  Takehiko Manabe; Soichi Oka; Kenji Ono
Journal:  Surg Case Rep       Date:  2020-07-28

5. 

Authors:  Adenauer Marinho de Oliveira Góes; Bárbara Íris Mascarenhas; Sofia Cunha Rodrigues; Mariseth Carvalho de Andrade; Reinaldo Sergio Monteiro Franco
Journal:  J Vasc Bras       Date:  2016 Apr-Jun

Review 6.  Potential Molecular Pathways Related to Pulmonary Artery Aneurysm Development: Lessons to Learn from the Aorta.

Authors:  Jorge Nuche; Julián Palomino-Doza; Fernando Arribas Ynsaurriaga; Juan F Delgado; Borja Ibáñez; Eduardo Oliver; Pilar Escribano Subías
Journal:  Int J Mol Sci       Date:  2020-04-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.